Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP9ECK)

Drug Name

2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline Drug Info

Synonyms

Santoflex B; UNII-UT9B2V4JD4; USAF B-29; 2,2,4-Trimethyl-6-phenyl-1,2-dihydroquinoline; 3562-69-4; BRN 0185528; UT9B2V4JD4; CHEMBL93463; 6-Phenyl-2,2,4-trimethyldihydroquinoline; 1,2-Dihydro-2,2,4-trimethyl-6-phenylquinoline; Quinoline, 1,2-dihydro-2,2,4-trimethyl-6-phenyl-; 2,2,4-trimethyl-6-phenyl-1H-quinoline; AC1L2SCX; 2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline; 4-20-00-04116 (Beilstein Handbook Reference); SCHEMBL311413; DTXSID30189094; ZINC5315096; BDBM50066527; ACM3562694; LS-141859

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 77098
CAS Number: CAS 3562-69-4
TTD Drug ID: DMP9ECK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Progesterone receptor (PGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[2]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[3]
Ulipristal	DMBNI20	Contraception	QA21	Approved	[4]
Etonogestrel	DMKA8J4	Contraception	QA21	Approved	[5]
Megestrol	DMDH9KX	Breast cancer	2C60-2C65	Approved	[6]
Segesterone acetate; ethinyl estradiol	DMFEGB0	Contraception	QA21	Approved	[7]
Norgestimate	DMYP4XC	Acne vulgaris	ED80	Approved	[5]
Dydrogesterone	DMAKIDV	Menstrual disorder	GA20.3	Approved	[8]
Medroxyprogesterone	DMBGWPH	Solid tumour/cancer	2A00-2F9Z	Approved	[8]
Ethynodiol Diacetate	DMZM84R	Contraception	QA21	Approved	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Progesterone receptor (PGR)	TTUV8G9	PRGR_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore. J Med Chem. 1998 Aug 27;41(18):3461-6.
2	Clinical pipeline report, company report or official report of lipocine.
3	Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
4	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
5	Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
6	Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
7	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
8	Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
9	Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.